On April 18, Longxin Biotech released its 2023 annual report.
The annual report shows that in 2023, Longxin Biotech will achieve operating income of 202.35 million yuan, a year-on-year increase of 18.92%; The total profit is 19.63 million yuan, and the company's overall output in 2023 is twice that of the whole year of 2022. In 2023, it will achieve a dividend of 13.5 million yuan. Gross profit reached 72.28%.
However, it is worth noting that Longxin Bio's operating income has increased, but its net profit has decreased by 14.14% year-on-year to 17.476 million yuan. In 2023, Longxin Biotech's profit distribution plan is: based on the company's existing total share capital of 54 million shares, it will distribute 2.5 yuan (tax included) in cash to all shareholders for every 10 shares, with a total cash dividend of 13.5 million yuan, and the record date of this equity distribution is May 30, 2023, and the ex-dividend date is: May 31, 2023.
The following is the top five customers of Longxin Biotech, the largest customer is Shandong People's Pharmaceutical Co., Ltd., with annual sales of 12.84 million yuan, accounting for 6.34%.
The top 10 shareholders of Longxin Biotech are shown in the table below:
According to Longxin Bio's profit distribution plan, Liang Huiliang, who ranked fourth, and Xu Hongru, who ranked tenth, held a total of 1.635 million shares and paid a dividend of 408,750 yuan.